Obasi Investment Ltd v. Tibet Pharmaceuticals Inc

931 F.3d 179
CourtCourt of Appeals for the Third Circuit
DecidedJuly 23, 2019
Docket18-1849
StatusPublished
Cited by11 cases

This text of 931 F.3d 179 (Obasi Investment Ltd v. Tibet Pharmaceuticals Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Obasi Investment Ltd v. Tibet Pharmaceuticals Inc, 931 F.3d 179 (3d Cir. 2019).

Opinions

HARDIMAN, Circuit Judge.

This case comes to the Court as a certified interlocutory appeal. The sole question presented is whether, under Section 11 of the Securities Act of 1933, 15 U.S.C. § 77k, a nonvoting board observer affiliated with an issuer's placement agent is a "person who, with his consent, is named in the registration statement as being or about to become a director[ ] [or] person performing similar functions ...." Id. § 77k(a)(3).

We think not. As required by the text of § 77k(a)(3), our inquiry begins and ends with the registration statement's description of the Defendants. We hold as a matter of law that the Defendants' functions are not "similar" to those that board directors perform, so we will reverse the District Court's order and direct the entry of summary judgment for the Defendants.

I 1

Tibet Pharmaceuticals, Inc. is a holding company. Through an array of parent-subsidiary relationships and contractual rights, Tibet "effectively control[led]" Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (Yunnan), an operating company that manufactured and sold traditional Tibetan medicines. Dartell v. Tibet Pharm., Inc. , 2017 WL 1944106 , at *2 (D.N.J. May 10, 2017). This case involves Tibet's attempt to raise capital for those operations through an initial public offering (IPO).

Hayden Zou was an early investor in Tibet and the sole director of China Tibetan Pharmaceuticals Limited, a wholly owned subsidiary of Tibet. Tibet's ability to control Yunnan flowed through China Tibetan. In late 2009, Zou told L. McCarthy Downs, III, a managing director at the investment bank Anderson & Strudwick, Inc. (A&S), about Tibet. The two discussed the prospect of a Tibet IPO, and A&S later agreed to serve as Tibet's placement agent. Zou and Downs then worked together to bring Tibet public. Tibet's IPO registration statement became effective in late 2010.

Zou and Downs were neither signatories to the registration statement nor named in it as directors of Tibet. Instead, they were listed as nonvoting board observers chosen by A&S. Though Zou and Downs would have no formal powers or duties, the registration statement explained "they may nevertheless significantly influence the outcome of matters submitted to the Board of Directors for approval." App. 178.

As it turned out, the registration statement 2 omitted material negative information about Yunnan's finances. Yunnan had defaulted on a loan from the Chinese government a few months before Tibet's registration statement became effective and that default led to a judgment that required repayment within 60 days. Though the registration statement described a "long term loan," it said nothing about the default judgment.

Just before Tibet filed its amended final prospectus, the Chinese government froze all of Yunnan's assets. Tibet did not disclose that either. The IPO closed soon thereafter, and Tibet and its underwriters offered 3 million shares to the public at $ 5.50 per share. But Yunnan still hadn't paid what it owed, so the Agricultural Bank of China auctioned off the company's assets. This prompted the NASDAQ to halt trading in Tibet's stock, and its price plummeted.

Plaintiffs sued Zou, Downs, Tibet, A&S, the IPO's auditor, and several other Defendants on behalf of a class of stock purchasers. As relevant to this certified interlocutory appeal, Plaintiffs alleged Zou and Downs violated Section 11 of the Securities Act of 1933, 15 U.S.C. § 77k(a).

II

Section 11 imposes near-strict liability for untruths and omissions made in a registration statement. See In re Suprema Specialties, Inc. Sec. Litig. , 438 F.3d 256 , 269 (3d Cir. 2006). Unlike antifraud cases, a § 11 plaintiff need not allege scienter, reliance, 3 or loss causation. See In re Constar Int'l Inc. Sec. Litig ., 585 F.3d 774 , 782-783 (3d Cir. 2009) ; In re Morgan Stanley Info. Fund Sec. Litig. , 592 F.3d 347 , 359 (2d Cir. 2010). Congress imposed this in terrorem liability on those best positioned to ensure accurate disclosure. In re Lehman Bros. Mortg.-Backed Sec. Litig. , 650 F.3d 167 , 181 (2d Cir. 2011) (citing Herman & MacLean v. Huddleston , 459 U.S. 375 , 381-82 & n.13, 103 S.Ct. 683 , 74 L.Ed.2d 548 (1983) ).

Because § 11 is such strong medicine, and to meet its purpose of enforcing accurate registration statement disclosure, it applies only to limited and enumerated categories of defendants. See Herman & MacLean , 459 U.S. at 381-82 , 103 S.Ct. 683 ; Lehman Bros. , 650 F.3d at 185 ("It is precisely because § 11 'gives rise to liability more readily,' however, that it is [sic] applies 'more narrowly' than § 10(b)." (quoting Morgan Stanley , 592 F.3d at 359-60 )). Among those defendants is "every person who, with his consent, is named in the registration statement as being or about to become a director, person performing similar functions, or partner." 15 U.S.C. § 77k(a)(3).

The District Court, finding there were material issues of fact about whether Zou and Downs had been named as people "performing similar functions to a director," Dartell

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Glenmede Trust Co., N.A. v. Infinity Q Capital Mgt. LLC
Appellate Division of the Supreme Court of New York, 2026
HAMMOND v. KENVUE INC.
D. New Jersey, 2025
In Re SmileDirectClub, Inc. Securities Litigation
Court of Appeals of Tennessee, 2022
United States v. Robert Harra, Jr.
985 F.3d 196 (Third Circuit, 2021)
NIKOLOV v. LIVENT CORPORATION
E.D. Pennsylvania, 2020

Cite This Page — Counsel Stack

Bluebook (online)
931 F.3d 179, Counsel Stack Legal Research, https://law.counselstack.com/opinion/obasi-investment-ltd-v-tibet-pharmaceuticals-inc-ca3-2019.